Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OVADEX

Financiado

Cerrado

Defining the role of the tumor microenvironment in treatment resistance of OVAri...

Defining the role of the tumor microenvironment in treatment resistance of OVArian cancer through patient-Derived EXplants (OVADEX) Treatment resistance in ovarian cancer (OC) is common. Recent efforts have identified new treatment approaches with potential to improve its management, but their therapeutic effects are limited due to treatment resistances.Tumor... ver más

31/08/2024

KU Leuven

Presupuesto desconocido

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

KU Leuven

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2022-09-01
Fecha Fin: 2024-08-31

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Treatment resistance in ovarian cancer (OC) is common. Recent efforts have identified new treatment approaches with potential to improve its management, but their therapeutic effects are limited due to treatment resistances.Tumor microenvironment (TME) is emerging as a key contributor to treatment resistance, being the metabolic cross-talk between TME and OC one of the recently proposed mechanisms. The hosting lab has evidence that platinum-resistant OC cells have defects in serine biosynthesis which leads to an enhance uptake of serine. Importantly, exogenous serine is also required for some TME components, suggesting a possible competition for it and affecting their anti-cancer function. Thus, my working hypothesis is that metabolic cross-talk between TME and OC could involve serine metabolism, which could mediate treatment resistance. Unfortunately, there is a lack of preclinical models of OC that recapitulate TME to study its role. In this regard, the secondment lab developed a new ex vivo platform based on patient-derived explants (PDEs) that allows the study of TME interactions with cancer cells. In OVADEX, I will use PDEs to dissect the role of TME components in treatment response in OC, and particularly, in the metabolic reprogramming of cancer cells. My objectives are to generate OC PDEs and expose them to standard and emerging therapies, to define metabolic changes in OC cells and cellular and phenotypic changes in TME before and after treatment and to associate changes in TME and OC cells to serine metabolism and treatment resistance. To this end, I will integrate innovative techniques and the access of the hosting team to a unique registry of OC patients.Through this work, I aim to broaden my scientific expertise and my international network for pursuing an academic career in Europe. OVADEX will contribute to actualize many objectives outlined in my career development plan to become a PI in the field of preclinical models for cancer applications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores